Krystal Biotech (KRYS) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Twist Bioscience (TWST) has outperformed Krystal Biotech (KRYS) over the past year, gaining 400.2% versus a gain of 77.3%. Over five years, KRYS leads with a +566.2% price change compared with +38.0% for TWST. Twist Bioscience is the larger company by market cap ($10.03 billion vs $9.56 billion), about 1.0 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs +20.3%).
Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | TWST |
|---|---|---|
| Share price | $323.01 | $151.29 |
| Market cap | $9.56B | $10.03B |
| 1-day change | -0.48% | -2.80% |
| YTD return | +31.65% | +390.70% |
| 1-year return | +77.34% | +400.16% |
| 5-year return | +566.19% | +37.99% |
| P/E ratio (TTM) | 40.48 | — |
| Forward P/E | 34.66 | — |
| EPS (TTM) | $7.98 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $389.13M | $376.57M |
| Revenue growth (YoY) | +33.94% | +20.32% |
| Net income (latest FY) | $204.83M | $-77.67M |
| Gross margin | — | 50.72% |
| Operating margin | 41.45% | -36.18% |
| Net margin | 52.64% | -20.63% |
| 52-week high | $382.54 | $219.71 |
| 52-week low | $179.19 | $23.30 |
| Distance from 52-week high | -15.56% | -31.14% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +21.39% | -11.59% |
| Average volume | 380.77K | 1.99M |
| Shares outstanding | 29.60M | 66.30M |
| Employees | 295 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed KRYS by 322.8 percentage points over the past year.
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +20.32%).
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
KRYS vs TWST FAQ
Which is bigger, Krystal Biotech or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.03B compared with $9.56B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, KRYS or TWST?
TWST returned +400.16% over the past 12 months, compared with +77.34% for KRYS (price return, excluding dividends). Past performance does not predict future results.
Are Krystal Biotech and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.